About this trial
1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity.
Inclusion criteria:
1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).
b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.
Trial design
Treatments tested in this trial
- Detection of TNFAIP3 gene expression by real time PCR.
Treatment groups
Locations
Sponsors and collaborators
Asmaa Hassan mohamed Abdel Mawjoud
Lead sponsor
Assiut University
Sponsor institution
Assiut University
Collaborator